Akari Therapeutics PLC (AKTX NASDAQ) stock market data APIs
$0.7922
0.09(11.4%)
as of September 18, 2025
Try our APIs with
free plan!
Akari Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Prev. Close
0.7922
Open
0.8859
High
0.9024
Low
0.7891
52 wk Range
0.5714-3.85
Market Cap
25 883 K
P/E Ratio
0
Shares Outstanding
32 615 K
EPS
-0.06
Beta
0.271
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akari Therapeutics PLC data using free add-ons & libraries
Get Akari Therapeutics PLC Fundamental Data
Akari Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -12 783 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akari Therapeutics PLC News
New
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts were tracking higher Thursday mor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
CGTX, RVPH, SHOT, SONN, AKTX Rally After-Hours On Clinical Updates And Fed Rate Cut Momentum
(RTTNews) - Biotech and healthcare stocks continue to respond sharply to progress in clinical trials, regulatory developments, and broader economic indicators. With the Federal Reserve initiating its ...
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announ...
European Equities Traded in the US as ADRs Fall in Friday Trading
European equities traded in the US as American depositary receipts fell late Friday morning with the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
